Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 249

1.

Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.

Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P, Haentjens P, Lyles KW.

J Am Geriatr Soc. 2010 Feb;58(2):292-9. doi: 10.1111/j.1532-5415.2009.02673.x. Epub 2010 Jan 8.

2.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial.

N Engl J Med. 2007 May 3;356(18):1809-22.

3.

Once-yearly zoledronic acid in older men compared with women with recent hip fracture.

Boonen S, Orwoll E, Magaziner J, Colón-Emeric CS, Adachi JD, Bucci-Rechtweg C, Haentjens P, Kaufman JM, Rizzoli R, Vanderschueren D, Claessens F, Sermon A, Witvrouw R, Milisen K, Su G, Lyles KW; HORIZON Recurrent Fracture Trial.

J Am Geriatr Soc. 2011 Nov;59(11):2084-90. doi: 10.1111/j.1532-5415.2011.03666.x. Epub 2011 Oct 21.

PMID:
22091563
4.

Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.

Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA; HORIZON Pivotal Fracture Trial.

J Clin Endocrinol Metab. 2009 Sep;94(9):3215-25. doi: 10.1210/jc.2008-2765. Epub 2009 Jun 30.

5.
6.

[Zoledronic acid reduces risk of any new clinical fracture and risk of death after surgical repair of a low-trauma hip fracture].

Leszczyński P.

Chir Narzadow Ruchu Ortop Pol. 2010 May-Jun;75(3):168-71. Review. Polish.

PMID:
21038635
7.

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R.

J Bone Miner Res. 2012 Feb;27(2):243-54. doi: 10.1002/jbmr.1494. Erratum in: J Bone Miner Res. 2012 Dec;27(12):2612.

8.

Association between timing of zoledronic acid infusion and hip fracture healing.

Colón-Emeric C, Nordsletten L, Olson S, Major N, Boonen S, Haentjens P, Mesenbrink P, Magaziner J, Adachi J, Lyles KW, Hyldstrup L, Bucci-Rechtweg C, Recknor C; HORIZON Recurrent Fracture Trial.

Osteoporos Int. 2011 Aug;22(8):2329-36. doi: 10.1007/s00198-010-1473-1. Epub 2010 Dec 9.

PMID:
21153021
9.

[Zoledronic acid for preventing fractures. HORIZON trial (Health Outcomes and Reduced Incidence with Zoledronic acid ONce yearly)].

Ringe JD, Nitschmann S.

Internist (Berl). 2008 Apr;49(4):502-4. doi: 10.1007/s00108-008-2067-2. German. No abstract available.

PMID:
18305914
10.

The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis.

Hwang JS, Chin LS, Chen JF, Yang TS, Chen PQ, Tsai KS, Leung PC.

J Bone Miner Metab. 2011 May;29(3):328-33. doi: 10.1007/s00774-010-0223-y. Epub 2010 Oct 5.

PMID:
20922438
11.

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.

Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS.

J Bone Miner Res. 2010 Oct;25(10):2239-50. doi: 10.1002/jbmr.119.

12.

Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.

Woodis CB.

Ann Pharmacother. 2008 Jul;42(7):1085-9. doi: 10.1345/aph.1K652. Epub 2008 May 27.

PMID:
18505912
13.

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.

Bone. 2007 Jul;41(1):122-8. Epub 2007 Mar 24.

PMID:
17468062
14.

Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.

John Camm A.

Clin Ther. 2010 Mar;32(3):426-36. doi: 10.1016/j.clinthera.2010.03.014. Review.

PMID:
20399982
15.

Fracture risk and zoledronic acid therapy in men with osteoporosis.

Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E.

N Engl J Med. 2012 Nov 1;367(18):1714-23. doi: 10.1056/NEJMoa1204061.

16.

Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial.

Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick NM.

JAMA Intern Med. 2015 Jun;175(6):913-21. doi: 10.1001/jamainternmed.2015.0747.

17.

The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT).

Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R.

J Bone Miner Res. 2015 May;30(5):934-44. doi: 10.1002/jbmr.2442.

18.

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators.

JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136. Erratum in: JAMA. 2017 Jan 24;317(4):442.

PMID:
27533157
19.

The role of zoledronic acid in the management of osteoporosis.

Maricic M.

Clin Rheumatol. 2010 Oct;29(10):1079-84. doi: 10.1007/s10067-010-1486-3. Epub 2010 Jun 11. Review.

PMID:
20544246
20.

Zoledronic acid and clinical fractures and mortality after hip fracture.

Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial.

N Engl J Med. 2007 Nov 1;357(18):1799-809. doi: 10.1056/NEJMoa074941. Epub 2007 Sep 17.

Supplemental Content

Support Center